share_log

HC Wainwright & Co. Reinstates Buy on Bellerophon Therapeutics, Maintains $30 Price Target

HC Wainwright & Co. Reinstates Buy on Bellerophon Therapeutics, Maintains $30 Price Target

HC Wainwright & Co.恢復對Bellerophon Therapeutics的買入,維持30美元的目標股價
Benzinga ·  2023/05/17 06:16

HC Wainwright & Co. analyst Andrew Fein reinstates Bellerophon Therapeutics (NASDAQ:BLPH) with a Buy and maintains $30 price target.

HC Wainwright & Co. 分析師安德魯·費恩恢復了Bellerophon Therapeutics(納斯達克股票代碼:BLPH)的買入並維持了30美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論